MTST MetaStat Inc (CE)

CEO Oscar L. Bronsther to Present on Tuesday, January 13 at 10:30 AM PT

MetaStat, Inc. (OTCQB:MTST), a molecular diagnostic company focused on developing and commercializing epigenetic-based diagnostic tests for early and reliable prediction of systemic metastasis, will be a presenting company at the Biotech Showcase™ 2015 Conference to be held at the Parc 55 Wyndham San Francisco–Union Square Hotel in San Francisco, CA.

Oscar L. Bronsther, M.D., Chief Executive Officer and Chief Medical Officer of MetaStat, will give a presentation on Tuesday, January 13 at 10:30 AM PT on the current status of the Company’s development of diagnostic tests for the early and reliable prediction of systemic metastasis.

Biotech Showcase is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry’s largest annual healthcare investor conferences. Now in its seventh year, this rapidly growing conference features multiple tracks of presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings. In addition to biopharmaceutical and life science company executives, Biotech Showcase delegates include investors in private and public companies, sector analysts, bankers and industry professionals.

About MetaStat, Inc.

MetaStat, Inc (MTST) is a molecular diagnostic company that develops and commercializes diagnostic tests for early and reliable prediction of systemic metastasis, the process by which cancer spreads from a primary tumor through the bloodstream to other areas of the body. MetaStat is focused on breast, prostate, lung and colorectal cancers, where systemic metastasis is responsible for approximately 90% of all deaths. The Company’s function-based diagnostic platform technology is based on the identification and understanding of the pivotal role of the mena protein and its isoforms, a common pathway for the development of systemic metastatic disease in all epithelial-based solid tumors. Both the MetaSite Breast™ and MenaCalc™ assays are designed to accurately stratify patients based on their individual risk of metastasis and to provide physicians with clinically actionable information to better "customize" cancer treatment. MetaStat’s testing platform improves treatment planning decisions by positively identifying patients with a high-risk of metastasis who need aggressive therapy and by sparing patients with a low-risk of metastasis from the harmful side effects and expense of chemotherapy. The company is based in Boston.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including those set forth in the Company's Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the company undertakes no obligation to update such statements.

Media:Dian Griesel Int’l. for MetaStatSusan Forman, 212-825-3210sforman@dgicomm.comorInvestors:MetaStat, Inc.Daniel Schneiderman, 212-608-0827Vice Presidentdan@metastat.com

MetaStat (CE) (USOTC:MTST)
Graphique Historique de l'Action
De Jan 2025 à Fév 2025

MetaStat (CE) (USOTC:MTST)
Graphique Historique de l'Action
De Fév 2024 à Fév 2025